tiprankstipranks
China Regenerative Medicine International Limited (HK:8158)
:8158
Hong Kong Market
8158
China Regenerative Medicine International Limited
RESEARCH TOOLSreports

China Regenerative Medicine International Limited (8158) Income Statement

Compare
0 Followers

China Regenerative Medicine International Limited Income Statement

Last quarter (Q2 2024), China Regenerative Medicine International Limited's total revenue was HK$29.89M, a decrease of -35.07% from the same quarter last year. In Q2, China Regenerative Medicine International Limited's net income was HK$8.41M. See China Regenerative Medicine International Limited’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
HK$ 69.49MHK$ 231.61MHK$ 282.90MHK$ 185.34MHK$ 47.97M
Gross Profit
HK$ 19.42MHK$ 37.62MHK$ 67.73MHK$ 45.01MHK$ 28.92M
Operating Expenses
HK$ 19.42MHK$ 32.61MHK$ 6.01MHK$ 181.01MHK$ 250.13M
Depreciation and Amortization
HK$ 11.32MHK$ 5.39MHK$ 78.00KHK$ 1.73MHK$ 51.69M
EBITDA
HK$ -95.40MHK$ 14.44MHK$ 64.66MHK$ -122.46MHK$ -267.63M
Operating Income
HK$ -109.12MHK$ 8.62MHK$ 64.59MHK$ -128.14MHK$ -224.14M
Other Income/Expenses
HK$ 1.42MHK$ -3.54MHK$ 2.66MHK$ -135.93MHK$ -182.34M
Pretax Income
HK$ -107.70MHK$ 8.27MHK$ 64.29MHK$ -277.33MHK$ -456.64M
Net Income
HK$ -107.70MHK$ 4.55MHK$ 51.83MHK$ -289.71MHK$ -447.74M
Per Share Metrics
HK$ ―HK$ ―HK$ ―HK$ ―HK$ ―
Basic EPS
HK$ -0.38HK$ 0.02HK$ 0.18HK$ -1.80HK$ -5.09
Diluted EPS
HK$ -0.38HK$ 0.02HK$ 0.18HK$ -1.80HK$ -5.09
Weighted Average Shares Outstanding
286.41M 285.43M 285.43M 160.68M 87.93M
Weighted Average Shares Outstanding (Diluted)
286.41M 285.43M 285.43M 160.68M 87.93M
Currency in HKD

China Regenerative Medicine International Limited Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis